{"id":1373,"createDateTime":"2026-08-14T04:51:09.389Z","archiveDateTime":"2026-10-12T09:30:00.000Z","name":"Hormonal Acne Management for General Practice","image":"8980d52fa2537eff660b08b44f79752a006b26b23d223206ddf22a8a","imageThumbnail":"bb0b3a191abc66b9631de005b87931e2765d514fc7d71ae5d2fd8f57","about":"Acne is a common reason for presentation in general practice. Yet, recognising when hormonal factors are driving the condition, or when hormonal therapy should be considered, is challenging.¹ As evidence supporting hormonal treatments for acne accumulates,²,³ GPs need a practical, evidence-based approach for managing acne. \n\nIn this webinar, dermatologist Dr Alex Coe, gynaecologist Dr Nasreen Shamas, and GP Dr Anita Muñoz integrate current evidence into a practical framework for managing hormonal acne in women. Through a longitudinal patient case, the panel discusses acne pathophysiology, first-line management, indications for combined oral contraceptives and spironolactone, counselling strategies, practical prescribing considerations, when to investigate for underlying disorders, or refer for specialist care.³⁻⁵ \n\nThe webinar features an extensive live Q&A. Guided by a multidisciplinary panel, you will be exposed to challenging clinical scenarios and receive practical insights that can be applied in your practice.\n\n# Learning Outcomes\n1. Apply current evidence when choosing appropriate acne management for women, including hormonal and non-hormonal options.\n2. Review the evidence base and risk profile of hormonal acne treatment options - including combined oral contraceptives and spironolactone - to support shared decision-making.\n3. Identify when to refer a patient with hormonal acne, including recognising signs that warrant further endocrine investigation.\n\n***This activity has Reviewing Performance and Measuring Outcomes activities available by clicking the RP and MO buttons above.***\n\n# Provider\nThe Provider of this activity is [Praxhub](/orgs/1). Praxhub is an accredited Major Provider under the RACGP CPD Program. For any questions regarding this activity please contact support@praxhub.com.\n\n# References:  \n1. Bagatin E, et al. An Bras Dermatol. 2019;94(1):62-75. \n2.Smith CA, et al. Dermatol Ther (Heidelb). 2025;15:45-59. \n3. Therapeutic Guidelines. Dermatology. 2026. \n4. RANZCOG. C-Gyn 3 Contraception (incorporating C-Gyn 3.12). 2024. \n5. Therapeutic Guidelines. Sexual and Reproductive Health. 2026. ","type":"zoom-webinar","summaryViewCount":124,"startDateTime":"2026-10-08T08:30:00.000Z","durationSecs":5400,"organisation":{"id":101,"name":"Arrotex","logoImage":"343d2282723763f021df947917df828894bcf90cd0942a7b794bdcd8","logoImageThumbnail":"4cb9c205c6d9ce99135b8445d977a6b5da5a4f07cbd1b9811fbd93f2","industry":"Pharmaceutical"},"provider":{"id":1,"name":"Praxhub","logoImage":"7d8c82e84cfeb7556fa842c1980c93b8144ab0959b0630c17e557baf","logoImageThumbnail":"78ba1e568155afb45aa67fc6f7337c076b0a1aa9182ceb80ac9b1095","industry":"Health Technology"},"commentCount":0,"likeCount":2,"presenters":[{"id":56042,"specialty":{"id":53,"name":"Dermatology"},"name":"Alex Coe","title":"Dermatologist","profileImage":"64e59d9e56a37101e56abbf99030a5430695899dacc5277668da2a39","profileImageThumbnail":"a8fb7447663345f7ed9be386847a13ab27e0d85a3dc7954dd52d7b4f"},{"id":19033,"specialty":{"id":74,"name":"Obstetrics and Gynaecology"},"name":"Nasreem Shammas","title":"Gynaecologist/Obstetrician","profileImage":"d68b9ec4bd0e2ea1860c0fd4cc2330ad8290e87c2d60f34e4708e06d","profileImageThumbnail":"efd40db04479f1966333015562e3614013a1c9b94848e7a691133a04"},{"id":4,"specialty":{"id":94,"name":"General Practice"},"name":"Dr Anita Muñoz","title":"General Practitioner","profileImage":"34b5c169049fb68bb5241af190b9342cfe72abc821bdce7a326f073f","profileImageThumbnail":"9fa1702663862484826e9cc0ef4a3ca5f2749852a822ded1a74663df"}],"relatedEducation":[{"id":1363,"name":"Oral Contraception: From Evidence to Practice ","image":"42d0a4f8a46f82c540c4c00afded1b3fc29d0ff0c0c808504d3cc458","imageThumbnail":"4b3f571a5a638bcdc9c3d417204de62c4244bd5b7e63d21fe20d6a61","type":"zoom-webinar","startDateTime":"2026-09-09T09:30:00.000Z","durationSecs":5400,"associationEducationTypes":["EA","MO","RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1371,"name":"Fracture risk perception and medication adherence","image":"8a32746a58f9ae41f671a7e9c947bb28f50471654044468665d3c5e7","imageThumbnail":"0563278e7f8893527677202c291cc4fc492c520ca53ccc1b743c91e6","type":"video","startDateTime":null,"durationSecs":454,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1370,"name":"Pharmacological considerations for long-term antiresorptive drug (ARD) therapy ","image":"486aaf82a6cd773abd54f88e7e0df641b671075061b3281e755c87af","imageThumbnail":"bf7fe9ca785b08607ae90187607860a533437433ba322ada091c4858","type":"video","startDateTime":null,"durationSecs":677,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1369,"name":"Medication-Related Osteonecrosis of the Jaw (MRONJ) and Osteoporosis","image":"8c4c071a6aaf8b1a9bcb1fd512eb112139c29ab8a970878215410ac9","imageThumbnail":"c5c976a9d9686a6b4364971a7987bb1e88ebae607f5ffcfb4dc3ea69","type":"video","startDateTime":null,"durationSecs":475,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1368,"name":"Osteoporotic Fracture vs Atypical Femoral Fracture (AFF)","image":"e47038a006cf6a26f6fcc26839a6a41a501306708d30a1df05682b1b","imageThumbnail":"365e97ca3567b7d1accf0e2f7a837e17c9f3e7b999384095779d33c8","type":"video","startDateTime":null,"durationSecs":370,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1367,"name":"Diagnosing osteoporosis and the latest treatment pathways","image":"4086d7dafc37fcd4356cd14c54e79767426d7f838825d6adc9e4684a","imageThumbnail":"e92410f1c9fa8ea1dd05b02c7b9594a42922d0be0c0ec815fee88113","type":"video","startDateTime":null,"durationSecs":855,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}}]}